The strategic focus on rare disease with its clinical portfolio provides a compelling business model characterized by relatively shorter development timelines, reduced capital requirements and the potential for accelerated market entry. The company has collaboration agreements with the University of Michigan for preclinical development and Abbott for use of CardioMEMS HF System.
Cyborg Score Rationale
Cereno has two clinical-stage assets with positive data progressing to pivotal trials, recent financing ($665M), and strategic partnerships. However, clinical-stage biotech carries execution risk, and the company is pre-commercial with negative earnings.
Top Insights
Q325 results showed Phase II preparations for lead assets CS1 and CS014 with FDA submission of CS1 Phase IIb clinical trial protocol in December
CS014 development broadened to pulmonary hypertension associated with interstitial lung disease (PH-ILD) to target a severe condition with limited treatments, expected to strengthen positioning at lower cost with higher success probability
Headquartered in Gothenburg, Sweden with US subsidiary in Kendall Square, Boston, Massachusetts
Recent financing executed on premium terms limiting dilution, with proceeds supporting runway into Q427 if fully utilised
Named Competitors
Pulmonary Arterial Hypertension therapies — Established PAH market leader with multiple approved therapies
Idiopathic Pulmonary Fibrosis therapies — Market leader in IPF with approved antifibrotic agents
HDAC inhibitors in cardiovascular/pulmonary indications — Emerging competition in epigenetic modulation space
Recent Developments
(March 2026) CS014 development broadened to pulmonary hypertension associated with interstitial lung disease with Phase II initiation planned for Q1 2027
(December 2025) FDA submission of CS1 Phase IIb clinical trial protocol with decision expected mid-December
(December 2025) Announced up to SEK665m in financing across equity, debt and warrants at premium terms
(2025) Successful warrant exercise bringing in SEK76.7 million for subscription of shares at SEK1.60 per share
Open the full interactive Cereno Scientific AB (publ) report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.